Anne Heatherington | Head, Data Sciences Institute and R&D Chief Data & Technology Officer
Takeda

Anne Heatherington, R&D Chief Data & Technology Officer and Head, Data Sciences Institute Anne Heatherington, Ph.D., is the R&D Chief Data & Technology Officer and Head, Data Sciences Institute (DSI) at Takeda Pharmaceutical Company Ltd. and a member of the R&D Management Committee (RMC). Anne leads overall strategy and execution of all quantitative sciences post-close including biostatistics, global outcomes research, epidemiology and digital sciences. She will also enhance quantitative sciences capabilities through innovation and partnerships and expand digital presence and digital culture with an aim to accelerate new ways of thinking and working. Throughout her 20+ year career, Anne has led organizations and programs in large pharma, mid-size biotechs and start-up organizations. As a leader, she promotes an empowered and accountable culture and believes in the power of collaboration. Prior to Takeda, Anne served as Head of Clinical Development at Summit Therapeutics, a small biotech company. In this role, she also served as Program Lead for a phase 2 asset for Duchenne muscular dystrophy (DMD) where she focused on patient engagement and use of external data sources.   Prior to Summit, Anne worked for 13 years at Pfizer where she initially focused on Clinical Pharmacology across a range of therapeutic areas; she then took on a much broader role when she was appointed as Vice President and Head of Clinical Research in Sandwich UK. Her last Pfizer role was as Vice President and Head of Quantitative Clinical Sciences where she oversaw Clinical Pharmacology and Biostatistics supporting research and development activities across several Research Units (Inflammation & Immunology, Rare Diseases and Cardiovascular/Metabolic disorders). Anne received her bachelor’s degree in pharmacy from Queen’s University Belfast, Northern Ireland, and her Ph.D. in pharmacokinetics from the University of Manchester, England. She completed post-doctoral training in the Centre for Bioengineering at University of Washington, Seattle and spent her early career at Amgen Inc, Thousand Oaks, California.